



U.S. SECURITIES AND EXCHANGE COMMISSION

PDF Copy of Submission on SEC EDGAR system

This PDF document is a copy of the following submission on the SEC's EDGAR system:

Submission/Form 10-K

Filed 2013-02-22

Accession number 0000200406-13-000038

Submitted on EDGAR account of JOHNSON & JOHNSON, CIK 0000200406

This copy was generated on 2026-06-23.

The submission itself is available on SEC's public EDGAR database at:

<https://www.sec.gov/Archives/edgar/data/0000200406/000020040613000038/0000200406-13-000038-index.html>.

Additional submission information is available on [SEC.gov](https://www.sec.gov), including but not limited to whether any additional reporting entities are associated with the submission.

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 10-K

**ANNUAL REPORT PURSUANT TO SECTION 13 OF
THE SECURITIES EXCHANGE ACT OF 1934**

For the fiscal year ended December 30, 2012

Commission file number 1-3215

JOHNSON & JOHNSON

(Exact name of registrant as specified in its charter)

New Jersey

(State of incorporation)

22-1024240

(I.R.S. Employer Identification No.)

**One Johnson & Johnson Plaza
New Brunswick, New Jersey**

(Address of principal executive offices)

08933

(Zip Code)

Registrant's telephone number, including area code: **(732) 524-0400**

SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT

Title of each class	Name of each exchange on which registered
Common Stock, Par Value \$1.00	New York Stock Exchange

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☐

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes ☐ No ☐

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☐ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☐ No ☐

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☐ Smaller reporting company ☐
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☐

The aggregate market value of the Common Stock held by non-affiliates computed by reference to the price at which the Common Stock was last sold as of the last business day of the registrant's most recently completed second fiscal quarter was approximately \$186 billion.

On February 19, 2013, there were 2,795,319,117 shares of Common Stock outstanding.

DOCUMENTS INCORPORATED BY REFERENCE

Parts I, II and III: Portions of registrant's annual report to shareholders for fiscal year 2012 (the "Annual Report").
Parts I and III: Portions of registrant's proxy statement for its 2013 annual meeting of shareholders filed within 120 days after the close of the registrant's fiscal year (the "Proxy Statement").

Item		Page
	PART I	
1	Business	1
	General	1
	Segments of Business	1
	Geographic Areas	2
	Raw Materials	2
	Patents and Trademarks	2
	Seasonality	2
	Competition	2
	Research and Development	3
	Environment	3
	Regulation	3
	Available Information	3
1A.	Risk Factors	4
1B.	Unresolved Staff Comments	4
2	Properties	4
3	Legal Proceedings	5
4	Mine Safety Disclosures	5
	Executive Officers of the Registrant	5
	PART II	
5	Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	6
6	Selected Financial Data	6
7	Management’s Discussion and Analysis of Financial Condition and Results of Operation	6
7A.	Quantitative and Qualitative Disclosures About Market Risk	7
8	Financial Statements and Supplementary Data	7
9	Changes in and Disagreements With Accountants on Accounting and Financial Disclosure	7
9A.	Controls and Procedures	7
9B.	Other Information	7
	PART III	
10	Directors, Executive Officers and Corporate Governance	7
11	Executive Compensation	8
12	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	8
13	Certain Relationships and Related Transactions, and Director Independence	8
14	Principal Accountant Fees and Services	9
	PART IV	
15	Exhibits and Financial Statement Schedules	9
	Schedule II — Valuation and Qualifying Accounts	10
	Signatures	11
	Report of Independent Registered Public Accounting Firm on Financial Statement Schedule	13
	Exhibit Index	14

Pharmaceutical Segment

The Pharmaceutical segment achieved sales of \$25.4 billion in 2012, representing an increase of 4.0% over the prior year, with operational growth of 6.8% and a negative currency impact of 2.8%. U.S. sales were \$12.4 billion, an increase of 0.3%. International sales were \$12.9 billion, an increase of 7.9%, which included 13.6% operational growth and a negative currency impact of 5.7%.

Major Pharmaceutical Therapeutic Area Sales:*

(Dollars in Millions)	2012	2011	2010	% Change	
				'12 vs. '11	'11 vs. '10
Total Immunology	\$ 7,874	6,798	5,398	15.8 %	25.9
REMICADE®	6,139	5,492	4,610	11.8	19.1
SIMPONI®	607	410	226	48.0	81.4
STELARA®	1,025	738	393	38.9	87.8
Other Immunology	103	158	169	(34.8)	(6.5)
Total Infectious Diseases	3,194	3,189	3,033	0.2	5.1
INTELENCE®	349	314	243	11.1	29.2
LEVAQUIN®/FLOXIN®	75	623	1,357	(88.0)	(54.1)
PREZISTA®	1,414	1,211	857	16.8	41.3
Other Infectious Diseases	1,356	1,041	576	30.3	80.7
Total Neuroscience	6,718	6,948	6,644	(3.3)	4.6
CONCERTA®/methylphenidate	1,073	1,268	1,319	(15.4)	(3.9)
INVEGA®	550	499	424	10.2	17.7
INVEGA® SUSTENNA®/XEPLION®	796	378	152	**	**
RISPERDAL® CONSTA®	1,425	1,583	1,500	(10.0)	5.5
Other Neuroscience	2,874	3,220	3,249	(10.7)	(0.9)
Total Oncology	2,629	2,048	1,465	28.4	39.8
DOXIL®/CAELYX®	83	402	320	(79.4)	25.6
VELCADE®	1,500	1,274	1,080	17.7	18.0
ZYTIGA®	961	301	—	**	100.0
Other Oncology	85	71	65	19.7	9.2
Total Other	4,936	5,385	5,856	(8.3)	(8.0)
ACIPHEX®/PARIET®	835	975	1,006	(14.4)	(3.1)
PROCRIT®/EPREX®	1,462	1,623	1,934	(9.9)	(16.1)
Other	2,639	2,787	2,916	(5.3)	(4.4)
Total Pharmaceutical Sales	\$ 25,351	24,368	22,396	4.0 %	8.8

* Prior year amounts have been reclassified to conform to current year presentation.

** Percentage greater than 100%

Immunology products achieved sales of \$7.9 billion in 2012, representing an increase of 15.8% as compared to the prior year. The increased sales of SIMPONI® (golimumab) and REMICADE® (infliximab) were primarily due to market growth and the impact of the agreement with Merck & Co. Inc. (Merck). Effective July 1, 2011, distribution rights to REMICADE® and SIMPONI® in certain territories were relinquished to the Company by Merck. Additional contributors to the increase were sales of STELARA® (ustekinumab).

Infectious disease products achieved sales of \$3.2 billion in 2012, representing an increase of 0.2% as compared to the prior year. Major contributors were INCIVO® (telaprevir), the continued momentum in market share growth of PREZISTA® (darunavir), EDURANT® (rilpivirine) and INTELENCE® (etravirine) partially offset by lower sales of LEVAQUIN® (levofloxacin)/FLOXIN® (ofloxacin), due to the loss of market exclusivity in the U.S. in June 2011.

Neuroscience products sales were \$6.7 billion, a decline of 3.3% as compared to the prior year. Growth was impacted by generic competition for CONCERTA®/methylphenidate, RAZADYNE® (galantamine), RISPERDAL® (risperidone) and DURAGESIC®/Fentanyl Transdermal (fentanyl transdermal system). A decline in the Company's long-acting injectable